Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of CPX-351 for Treatment of AML or Higher Risk MDS Relapsed or Refractory to Prior Therapy With Hypomethylating (HMA) Agent

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02019069
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:02.359437+00:00
Published At
2019-01-15T00:00:00+00:00
Record Updated At
2019-01-22
Results Posted At
2019-01-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adult Acute Erythroid Leukemia (M6)", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-01-22"
protocolSection.identificationModule.nctId
"NCT02019069"
protocolSection.identificationModule.officialTitle
"A Phase II Study of CPX-351 for Treatment of AML or Higher Risk MDS Relapsed or Refractory to Prior Therapy With Hypomethylating (HMA) Agent"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2019-01-15"

Study condition terms

  • Adult Acute Erythroid Leukemia (M6) (protocolSection.conditionsModule.conditions)
  • Adult Acute Megakaryoblastic Leukemia (M7) (protocolSection.conditionsModule.conditions)
  • Adult Acute Minimally Differentiated Myeloid Leukemia (M0) (protocolSection.conditionsModule.conditions)
  • Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloblastic Leukemia With Maturation (M2) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloblastic Leukemia Without Maturation (M1) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With Del(5q) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myelomonocytic Leukemia (M4) (protocolSection.conditionsModule.conditions)
  • de Novo Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Previously Treated Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Secondary Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.